Eclipse 2000 To Compete Against PLC's Heart Laser In TMR Market
This article was originally published in The Gray Sheet
Executive Summary
PLC Medical's Heart Laser 1% perioperative mortality in stable angina patients may be viewed by cardiac surgeons as a significant advantage over the 5% rate for the Eclipse 2000, which was recommended for approval by FDA's Circulatory System Devices Panel at its Oct. 27 meeting. Both lasers are used in transmyocardial revascularization procedures to treat angina.
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.